Dr. Amy Beth Devlin, MD

Dr. Devlin practices at Hallmark Health Medical Associates Inc in Reading, Massachusetts.

Dr. Devlin's NPI, 1417120726, was assigned on April 8, 2008. Dr. Devlin graduated from Jacobs School of Medicine and Biomedical Sciences in 2008. Dr. Devlin holds Massachusetts license 249776.

Dr. Devlin's primary practice is Hallmark Health Medical Associates Inc, at 30 Newcrossing Rd, Reading, MA 01867 in Middlesex County. The practice phone is (781) 338-7521.

Dr. Devlin's primary practice is Hallmark Health Medical Associates Inc in Reading, Massachusetts. Dr. Devlin is also affiliated with Salem Hospital. The medical group on file is Tufts Medical Center Community Care. Dmand AI also links Dr. Devlin to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Devlin practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Devlin's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Devlin is board certified in internal medicine by the American Board of Internal Medicine. Dr. Devlin is licensed in Massachusetts.

Dmand AI lists arteritis, arthritis, chronic anemia, dry eye, enthesopathy in foot or ankle, fibromyalgia and chronic pain, fluid in a joint and gout among the conditions Dr. Devlin treats.

CMS data shows 872 Medicare services from Dr. Devlin across 5 procedure codes in 2024, for 332 Medicare patients. Medicare paid $48,479 for them. Every service was in an office.

CMS counts 332 Medicare patients who saw Dr. Devlin in 2024. The largest group is 65 to 74, with 149 patients. 75% of them have arthritis, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.27, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Devlin's median patient age at 66, with 79% women.

In 2024, Dr. Devlin wrote 2,088 Medicare Part D claims for 340 patients. 74% of them were for generic drugs. CMS names the drug for 1,909 of them, across 32 drugs with 11 or more claims each, at $2,711,348 in total drug cost. In 2023, CMS named 1,967 claims across 32 drugs.

Dr. Devlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Devlin as offering telehealth.

Dmand AI links 6 papers to Dr. Devlin, published from 2011 to 2014. 2013 was the busiest year, with 3. The most frequent topics are Gene Expression Regulation and Lupus Erythematosus, Systemic. Dr. Devlin's most frequent co-authors are Vasileios C. Kyttaris, MD, George C. Tsokos, MD and Jeremy R. Beitler, MD.

CMS Open Payments shows 16 general payments to Dr. Devlin from 5 drug and device companies from 2016 to 2022. Food and beverage make up the largest share, 84% of the total. Janssen Pharmaceuticals, Inc paid the most, $320.

Dmand AI lists 1 award for Dr. Devlin.

Dr. Devlin graduated from Jacobs School of Medicine and Biomedical Sciences in 2008.

Dr. Devlin is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.